GSK's Armala meets Phase III RCC endpoint

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) reported that Armala pazopanib met the primary endpoint of median progression-free survival (PFS) vs. placebo in a double-blind, international Phase III trial i...